Marked reduction of the alpha-fetoprotein levels among individuals with chronic hepatitis C, following Peg-interferon and ribavirin treatment

被引：1
|
作者：
Aladag, M [1 ]
Camci, C [1 ]
Huang, Y [1 ]
Wright, H [1 ]
Rizvi, S [1 ]
Gurakar, A [1 ]
Stokes, K [1 ]
Sebastian, A [1 ]
机构：
[1] Integris Baptist Med Ctr, Nazih Zuhdi Transplantat Inst, Div Liver Transplantat Med Hepatol, Oklahoma City, OK 73112 USA
来源：
JOURNAL OF CLINICAL GASTROENTEROLOGY | 2005年 / 39卷 / 10期
关键词：
D O I：
10.1097/01.mcg.0000180801.64575.4f
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：923 / 924
页数：2
相关论文
共 50 条
  • [31] COST-EFFECTIVENESS ANALYSIS OF PEG-INTERFERON ALPHA-2A PLUS RIBAVIRIN VERSUS CONVENTIONAL INTERFERON ALPHA-2A PLUS RIBAVIRIN FOR THE TREATMENT OF CHRONIC HEPATITIS C IN CHINA
    Chen, W.
    Wei, L.
    VALUE IN HEALTH, 2011, 14 (07) : A280 - A280
  • [32] Peg-Interferon in Acute and Chronic Hepatitis C: A Review
    Palumbo, Emilio
    AMERICAN JOURNAL OF THERAPEUTICS, 2009, 16 (06) : 573 - 578
  • [33] Effect of interferon therapy on serum alpha-fetoprotein levels in patients with chronic hepatitis C virus infection
    Franceschini, R
    Picciotto, A
    Cataldi, A
    Corsini, G
    Sinelli, N
    Bruno, E
    Barreca, T
    Rolandi, E
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1998, 59 (04): : 223 - 226
  • [34] Effects of ITPA polymorphism on decrease of hemoglobin during simeprevir, peg-interferon, and ribavirin combination treatment for chronic hepatitis C
    Morio, Kei
    Imamura, Michio
    Kawakami, Yoshiiku
    Morio, Reona
    Hatooka, Masahiro
    Kan, Hiromi
    Fujino, Hatsue
    Fukuhara, Takayuki
    Kobayashi, Tomoki
    Masaki, Keiichi
    Ono, Atsushi
    Nakahara, Takashi
    Urabe, Ayako
    Yokoyama, Satoe
    Nagaoki, Yuko
    Kawaoka, Tomokazu
    Hiraga, Nobuhiko
    Tsuge, Masataka
    Hiramatsu, Akira
    Hayes, C. Nelson
    Aikata, Hiroshi
    Ochi, Hidenori
    Chayama, Kazuaki
    HEPATOLOGY RESEARCH, 2016, 46 (12) : 1256 - 1263
  • [35] High dose daily consensus interferon and ribavirin is an effective option in chronic hepatitis C patients who are nonresponders to PEG-Interferon and ribavirin
    Rothstein, KD
    Koka, R
    Hargrove, H
    Fernandez, A
    Singh, S
    Araya, V
    Munoz, SJ
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (09): : S122 - S122
  • [36] Danazol in the treatment of thrombocytopenia associated with the use of peg-interferon alfa 2a and Ribavirin in patients with chronic hepatitis C
    Gomez-Galicia, Diana
    Cabrera-Alvarez, Guillermo
    Rodriguez-Fragoso, Lourdes
    Reyes-Esparza, Jorge
    FASEB JOURNAL, 2010, 24
  • [37] Interferon alpha and ribavirin in the treatment of children with chronic hepatitis C
    Magdalena Figlerowicz
    Wojciech Sluzewski
    Arleta Kowala-Piaskowska
    Iwona Mozer-Lisewska
    European Journal of Pediatrics, 2004, 163 : 265 - 267
  • [38] Interferon alpha and ribavirin in the treatment of children with chronic hepatitis C
    Figlerowicz, M
    Sluzewski, W
    Kowala-Piaskowska, A
    Mozer-Lisewska, I
    EUROPEAN JOURNAL OF PEDIATRICS, 2004, 163 (4-5) : 265 - 267
  • [39] PEG-interferon-alpha-2b and ribavirin treatment in children and adolescents with chronic hepatitis C
    Wirth, S
    Ballauff, A
    Kullmer, U
    Lang, T
    Wintermeyer, P
    Gerner, P
    HEPATOLOGY, 2004, 40 (04) : 344A - 344A
  • [40] Treatment of chronic hepatitis C with PEG-interferon alpha-2b and ribavirin:: 24 weeks of therapy are sufficient for HCV genotype 2 and 3
    Cornberg, M
    Hüppe, D
    Wiegand, J
    Felten, G
    Wedemeyer, H
    Manns, MP
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2003, 41 (06): : 517 - 522
12345